Format

Send to

Choose Destination
Breast Cancer Res. 2007;9(1):202.

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

Author information

1
University of California Los Angeles, Department of Medicine, Hematology-Oncology and Biological Chemistry, Molecular Biology Institute, Los Angeles, California 90095-1678, USA. rlandgraf@mednet.ucla.edu

Abstract

EGFR-type receptor tyrosine kinases achieve a broad spectrum of cellular responses by utilizing a set of structurally conserved building blocks. Based on available crystal structures and biochemical information, significant new insights have emerged into modes of receptor control, its deregulation in cancer, and the nuances that differentiate the four human receptors. This review gives an overview of current models of the control of receptor activity with a special emphasis on HER2 and HER3.

PMID:
17274834
PMCID:
PMC1851388
DOI:
10.1186/bcr1633
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center